PRF Technologies Ltd. (PRFX)

Agreement Initiates Data-Driven Technical Due Diligence of an Operational, Utility-Scale Solar Asset in Israel Agreement Initiates Data-Driven Technical Due Diligence of an Operational, Utility-Scale Solar Asset in Israel

TEL AVIV, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PRF Technologies (Nasdaq: PRFX) (“PRF” or the “Company”), through its DeepSolar™ AI-driven solar analytics business unit, today announced the signing of a software-as-a-service (SaaS) agreement with Shikun & Binui Energy for the deployment of DeepSolar at the 71 megawatt (MW) Satu Mare photovoltaic site in Romania. The Satu Mare project is a utility-scale solar plant owned and operated by Shikun & Binui Energy.

Patent filing follows acceptance into the NVIDIA Connect Program  Proprietary software targets weather forecast-driven revenue optimization, reduced penalty risk, and improved market performance for utility-scale solar assets TEL AVIV, Israel, Jan. 20, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) (formerly “PainReform”) today announced that it has filed a patent application covering proprietary methods for solar plant–level micro-climate modeling designed to significantly improve the accuracy of solar energy production forecasts in competitive electric utility markets.

Penny stock PainReform Ltd. (NASDAQ: PRFX) stock climbed on Friday following the company's recent announcement of a name change to PRF Technologies Ltd.

Shareholders Approved Name Change at January 6, 2026 Annual General Meeting as Company Evolves Beyond Single-Asset Focus Shareholders Approved Name Change at January 6, 2026 Annual General Meeting as Company Evolves Beyond Single-Asset Focus

TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operative pain management, together with its majority-owned subsidiary LayerBio, Inc., today announced safety data supporting the continued development of OcuRing™-K drop-less, sustained-release ocular drug delivery platform for use in cataract surgery.

PainReform (NASDAQ: PRFX - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Insider and Institutional Ownership 37.3% of PainReform shares

New lifecycle-wide audit platform provides complete data coverage, advanced diagnostics, and rapid turnaround, supporting investors, operators, insurers and lenders across commissioning, underperformance, warranty expiry, and asset transactions New lifecycle-wide audit platform provides complete data coverage, advanced diagnostics, and rapid turnaround, supporting investors, operators, insurers and lenders across commissioning, underperformance, warranty expiry, and asset transactions

AI-driven monitoring and analytics solutions addressing the growing demand for energy efficiency in large-scale solar and critical infrastructure projects across the Middle East. TEL AVIV, Israel, Dec. 30, 2025 /PRNewswire/ -- BladeRanger (TASE: BLRN), a provider of drone-based inspection, maintenance, and AI-driven analytics solutions for green energy and critical infrastructure, today announced its participation in Abu Dhabi Sustainability Week (ADSW), a leading global platform dedicated to sustainability, clean energy, and climate-related innovation.

TEL AVIV, Israel, Dec. 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) today announced that its pharmaceutical division has completed an R&D assessment of LayerBio's proprietary drop-less, sustained-release ocular drug-delivery platform.

Development plan positions OcuRing™-K for advancement in the fast-growing, multi-billion-dollar global cataract surgery market Development plan positions OcuRing™-K for advancement in the fast-growing, multi-billion-dollar global cataract surgery market

PainReform Ltd. (NASDAQ: PRFX - Get Free Report) dropped 1.3% during mid-day trading on Monday. The stock traded as low as $0.87 and last traded at $0.8838. Approximately 96,867 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 695,639 shares. The stock had previously closed at $0.8955. Analyst

TEL AVIV, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) today announced that DeepSolar, its solar energy business unit developing next-generation AI analytics, has advanced the development of its proprietary automated reporting engine, designed to transform how solar-asset performance is analyzed, understood, and communicated.

TEL AVIV, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced that DeepSolar, its solar energy business unit developing next-generation AI-driven solar analytics, was recently featured in a Watchlist Interview produced in collaboration with The Market Link, highlighting its participation in the NVIDIA Connect program.

TEL AVIV, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of AI-driven solar analytics technologies, today provided a business update for the six months ended June 30, 2025.

Shares of Israel-based pharmaceutical company PainReform (NASDAQ: PRFX) jumped nearly 130% on Tuesday after its renewable energy arm, DeepSolar, was accepted into the Nvidia (NASDAQ: NVDA) Connect Program.